Local Infusion

MYLOCALINFUSION.COM

PHESGO (COMBINATION OF PERTUZUMAB AND TRASTUZUMAB, HER2/NEU RECEPTOR ANTAGONISTS, AND HYALURONIDASE, AN ENDOGLYCOSIDASE) ORDER FORM

PATIENT INFORMATION

Patient Name: _____ DOB: _____

Mobile Number: _____ Patient Weight: _____kg

Allergies: _____

❑ New Start Therapy | ❑ Continuation of Therapy & Date of last dose (if applicable): _____

DIAGNOSIS (Provider must specify)

Use in combination with chemotherapy as:

- neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
- adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence

Use in combination with:

- docetaxel for treatment of patients with HER2- positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease

Malignant neoplasm of the female breast, ICD 10: C50:_____

PROVIDER INFORMATION

Provider Name (print name): _____ Provider NPI:_____

Signature: _____ Date: _____

Contact Name: _____ Phone: _____ Fax: _____

Email Address: _____

Prerequisites to treatment – ensure the following information is complete and attached with referral:

❑ Demographics ❑ Labs and tests supporting diagnosis ❑ Office/progress notes

PRE-MEDICATION (Not typically indicated)

❑ Acetaminophen (Tylenol) 500 mg PO

❑ Benadryl 25mg PO

❑ Famotidine 20 mg IV

❑ Cetirizine (Zyrtec) 10 mg PO

❑ Methylprednisolone (Solu-Medrol) 125 mg IVP

❑ Other: _____ Dose: _____ Route: _____

PHESGO (COMBINATION OF PERTUZUMAB AND TRASTUZUMAB, HER2/NEU RECEPTOR ANTAGONISTS, AND HYALURONIDASE, AN ENDOGLYCOSIDASE) ORDER FORM

MEDICATION

MEDICATION	DOSE	ROUTE	FREQUENCY
Phesgo	Initial dose: 1,200 mg pertuzumab 600 mg trastuzumab 30,000 units hyaluronidase followed by 600 mg pertuzumab 600 mg trastuzumab 20,000 units hyaluronidase	Sub q	Initial then every 3 weeks

LABS / SPECIAL INSTRUCTIONS